These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3937164)

  • 1. Plasma levels of exogenous thyrotropin-releasing hormone (TRH) in normal subjects: relationship to endocrine and behavioral effects.
    Loosen PT; Youngblood W; Dew B
    Pharmacopsychiatry; 1985 Nov; 18(6):325-9. PubMed ID: 3937164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human prolactin and thyrotropin concentrations in the serums of normal and hypopituitary children before and after the administration of synthetic thyrotropin-releasing hormone.
    Foley TP; Jacobs LS; Hoffman W; Daughaday WH; Blizzard RM
    J Clin Invest; 1972 Aug; 51(8):2143-50. PubMed ID: 4626583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism and excretion of exogenous thyrotropin-releasing hormone in humans.
    Bassiri RM; Utiger RD
    J Clin Invest; 1973 Jul; 52(7):1616-9. PubMed ID: 4198107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repetitive administration of thyrotropin-releasing hormone results in small elevations of serum thyroid hormones and in marked inhibition of thyrotropin response.
    Snyder PJ; Utiger RD
    J Clin Invest; 1973 Sep; 52(9):2305-12. PubMed ID: 4199417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of TRH during pregnancy.
    Bajoria R; Oteng-Ntim E; Peek MJ; Fisk NM
    Obstet Gynecol; 1997 Aug; 90(2):176-82. PubMed ID: 9241288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics and pharmacodynamics of protirelin (TRH) in man].
    Duntas L; Keck FS; Loos U; Pfeiffer EF
    Dtsch Med Wochenschr; 1988 Sep; 113(35):1354-7. PubMed ID: 3137012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of TRH on prolactin, plasma renin activity, water and electrolyte excretion in normal males.
    Epstein S; van Zyl-Smit R; le Roith D; Vinik A; Pimstone B
    Horm Metab Res; 1977 Nov; 9(6):495-8. PubMed ID: 412766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a pharmacokinetic model to characterize the thyrotropin (TSH) and prolactin (PRL) response to thyrotropin-releasing hormone (THR) in man.
    Perret G; Valensi P; Hugues JN; Vassy R; Uzzan B
    Methods Find Exp Clin Pharmacol; 1988 Jun; 10(6):387-91. PubMed ID: 3137402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-casomorphin inhibits thyrotropin secretion in rats.
    Mitsuma T; Nogimori T; Chaya M
    Exp Clin Endocrinol; 1984 Dec; 84(3):324-30. PubMed ID: 6441729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperthyroidism and subjects hyperresponding to thyrotropin. Importance of simultaneous thyrotropin and prolactin determination following administration of thyroid-releasing hormone].
    Schlienger JL; De Laharpe F; Reville P; Stephan F
    Sem Hop; 1980 May 8-15; 56(17-18):827-31. PubMed ID: 6248964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyrotropin-releasing hormone: pharmacokinetic and pharmacodynamic properties in chronic renal failure.
    Duntas L; Wolf CF; Keck FS; Rosenthal J
    Clin Nephrol; 1992 Oct; 38(4):214-8. PubMed ID: 1424308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physalaemin inhibits thyrotropin secretion in rats.
    Mitsuma T; Nogimori T; Chaya M
    Exp Clin Endocrinol; 1985 Jun; 85(3):319-25. PubMed ID: 3930270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum thyrotropin responses to synthetic thyrotropin-releasing hormone in normal children and hypopituitary patients. A new test to distinguish primary releasing hormone deficiency from primary pituitary hormone deficiency.
    Foley TP; Owings J; Hayford JT; Blizzard RM
    J Clin Invest; 1972 Feb; 51(2):431-7. PubMed ID: 4621544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations of thyroxine, 3,5,3'-triiodothyronine, thyrotropin, and prolactin in dogs before and after thyrotropin-releasing hormone administration.
    Kaufman J; Olson PN; Reimers TJ; Allen TA; Soderberg SF; Nett TM; Wheeler SL; Wingfield WE
    Am J Vet Res; 1985 Feb; 46(2):486-92. PubMed ID: 3922262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma clearance and plasma half-disappearance time of exogenous thyrotropin-releasing hormone and pyroglutamyl-N3im-methyl-histidyl prolineamide.
    Morley JE; Garvin TJ; Pekary AE; Utiger RD; Nair MG; Baugh CM; Hershman JM
    J Clin Endocrinol Metab; 1979 Mar; 48(3):377-80. PubMed ID: 107180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Submaximal plasma prolactin response to TRH and dopamine activity in man.
    Spoov J
    Pharmacopsychiatry; 1985 Nov; 18(6):330-2. PubMed ID: 3003766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control.
    Duntas L; Keck FS; Wolf C; Hauner H; Pfeiffer EF
    Thyroidology; 1991 May; 3(2):51-7. PubMed ID: 1726900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of TSH response to TRH as an independent variable.
    Loosen PT; Kistler K; Prange AJ
    Am J Psychiatry; 1983 Jun; 140(6):700-3. PubMed ID: 6405637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma prolactin response to submaximal stimulation by TRH and endogenous corticosteroids in man.
    Spoov J
    Pharmacopsychiatry; 1987 May; 20(3):96-8. PubMed ID: 3110801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactin releasing effects of TRH in the bovine and their depression by a prolactin inhibitor.
    Schams D
    Horm Metab Res; 1972 Sep; 4(5):405. PubMed ID: 4630331
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.